Contributions
Abstract: PB1942
Type: Publication Only
Background
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell proliferative disorder found in approximately 3% of the general population 50 years of age and older. MGUS is associated with progression to multiple myeloma or related malignancy at a rate of 1% per year. Thus the risk of malignancy for a 50-year-old patient with a 25-year life span is 25%.
Aims
We hypothesized that the presence of monoclonal free kappa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS), as detected by the serum free light chain (FLC) assay increases the risk of progression to malignancy.
Methods
90 Patients seen at the Hematology consultation from 2010 to 2015 with MGUS have a serum Mprotein less than 30 g/L, bone marrow plasma cells less than 10%, and no anemia, hypercalcemia, lytic bone lesions, or renal failure that would be indicative of a malignant plasma cell disorder.
Results
The median age at diagnosis of MGUS was 59 years (35-92years). 62 Womans and 28 Mans Sex ratio=2.2. Serum electrophoresis and immunoelectrophoresis or immunofixation was done in 85 patients. Of these, The median serum M protein size at diagnosis was 12 g/L (1.7-28.5g/L)
Conclusion
A novel, highly sensitive serum free light chain (FLC) assay is now available for clinical practice.The risk of progression in patients with an abnormal FLC ratio was significantly higher compared with patients with a normal ratio, and was independent of the size and type of the serum monoclonal (M) protein. Patients with an abnormal serum FLC ratio, non–immunoglobulin G (non-IgG) MGUS, and a high serum M protein level (> 15 g/L) had a major risk of progression.
Session topic: 13. Myeloma and other monoclonal gammopathies - Biology
Keyword(s): Free light chain, MGUS
Abstract: PB1942
Type: Publication Only
Background
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell proliferative disorder found in approximately 3% of the general population 50 years of age and older. MGUS is associated with progression to multiple myeloma or related malignancy at a rate of 1% per year. Thus the risk of malignancy for a 50-year-old patient with a 25-year life span is 25%.
Aims
We hypothesized that the presence of monoclonal free kappa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS), as detected by the serum free light chain (FLC) assay increases the risk of progression to malignancy.
Methods
90 Patients seen at the Hematology consultation from 2010 to 2015 with MGUS have a serum Mprotein less than 30 g/L, bone marrow plasma cells less than 10%, and no anemia, hypercalcemia, lytic bone lesions, or renal failure that would be indicative of a malignant plasma cell disorder.
Results
The median age at diagnosis of MGUS was 59 years (35-92years). 62 Womans and 28 Mans Sex ratio=2.2. Serum electrophoresis and immunoelectrophoresis or immunofixation was done in 85 patients. Of these, The median serum M protein size at diagnosis was 12 g/L (1.7-28.5g/L)
Conclusion
A novel, highly sensitive serum free light chain (FLC) assay is now available for clinical practice.The risk of progression in patients with an abnormal FLC ratio was significantly higher compared with patients with a normal ratio, and was independent of the size and type of the serum monoclonal (M) protein. Patients with an abnormal serum FLC ratio, non–immunoglobulin G (non-IgG) MGUS, and a high serum M protein level (> 15 g/L) had a major risk of progression.
Session topic: 13. Myeloma and other monoclonal gammopathies - Biology
Keyword(s): Free light chain, MGUS